Phase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer

BACKGROUND: Biologically targeted therapies have been postulated as a viable strategy to improve outcomes for women with ovarian cancer. We assessed the safety, tolerance, pharmacokinetics, relevant circulating and image-derived biomarkers, and clinical activity of combination aflibercept and doceta...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Coleman, Robert L, Duska, Linda R, Ramirez, Pedro T, Heymach, John V, Kamat, Aparna A, Modesitt, Susan C, Schmeler, Kathleen M, Iyer, Revathy B, Garcia, Michael E, Millera, Debbie L, Jackson, Edward F, Ng, Chaan S, Kundra, Vikas, Jaffe, Robert, Sood, Anil K
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3444811/
https://ncbi.nlm.nih.gov/pubmed/21992853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(11)70244-3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires